RecruitingNCT04519619

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Drug Use Investigation for Eylea for Neovascular Glaucoma (NVG)

Sponsor

Bayer

Enrollment

480 participants

Start Date

Nov 27, 2020

Study Type

OBSERVATIONAL

Conditions

Neovascular Glaucoma

Summary

This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is collecting real-world safety data on aflibercept eye injections (a treatment that reduces abnormal blood vessel growth in the eye) in Japanese patients with neovascular glaucoma — a serious form of glaucoma caused by new abnormal blood vessels blocking fluid drainage in the eye. **You may be eligible if...** - You have been diagnosed with neovascular glaucoma - You have received aflibercept (IVT-AFL) injections as part of your standard treatment in Japan **You may NOT be eligible if...** - You have a condition listed as a contraindication to aflibercept on the Japanese approved label - You are being treated for a different eye condition (other than neovascular glaucoma) with this drug Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAflibercept (Eylea, BAY86-5321)

Administration by intravitreal injection

Locations(1)

Many locations

Multiple Locations, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04519619

Related Trials

Intravitreous Avastin for diseases of ocular angiogensis

ACTRN12607000244404